Herbalife (NYSE: HLF) reported financial results for the first quarter ended March 31, 2025.
“Our first quarter results were strong, and we raised our full-year 2025 Adjusted EBITDA2 expectations. Our recent acquisitions strengthen our position and support our commitment to transformative growth,”
stated Stephan Gratziani, President and incoming CEO (effective May 1, 2025).
First Quarter 2025: Key Highlights
Net sales of $1.2 billion at midpoint of guidance range
Down 3.4% vs. Q1 ‘24
Includes 480 basis points of FX headwinds
Up 1.4% year-over-year on constant currency basis1; at low end of guidance range
Net income of $50.4 million; adjusted net income2 $59.9 million
Adjusted EBITDA1 of $164.9 million exceeds guidance
Adjusted EBITDA2 at constant currency1 of $181.5 million exceeds guidance
Adjusted EBITDA2 margin up 260 basis points vs. Q1 ‘24
Credit Agreement EBITDA2 of $192.0 million
Total leverage ratio reduced to 3.0x at March 31
Diluted EPS of $0.49; adjusted diluted EPS2 $0.59
Recent Developments
Completed acquisitions of certain assets of Pro2col Health LLC and Pruvit Ventures, Inc.
Formed and obtained a 51% ownership interest in HBL Link Bioscience LLC, which acquired assets of Link BioSciences Inc.
Management Commentary
Herbalife reported first quarter 2025 net sales of $1.2 billion, down 3.4% year-over-year, including 480 basis points of foreign currency headwinds. On a constant currency basis1, net sales increased 1.4% year-over-year, marking the second consecutive quarter of